Targets for Cancer Immunotherapy: A Deep Dive Seminar Series is supported, in part, by grants from Alkermes, Inc., Genentech, a member of the Roche Group, Incyte Corporation, Merck & Co., Inc., and Regeneron Pharmaceuticals (as of 10/05/2021).